title: Neoadjuvant Systemic Therapy in Breast Cancer: Association of Contrast-enhanced MR Imaging Findings, Diffusion-weighted Imaging Findings, and Tumor Subtype with Tumor Response.
abstract: Purpose To investigate the performance of tumor subtype and various magnetic resonance (MR) imaging parameters in the assessment of tumor response to neoadjuvant systemic therapy (NST) in patients with breast cancer and to outline a model of pathologic response, considering pathologic complete response (pCR) as the complete absence of any residual invasive cancer or ductal carcinoma in situ (DCIS). Materials and Methods This was an institutional review board-approved retrospective study, with waiver of the need to obtain informed consent. From November 2009 to December 2014, 111 patients with histopathologically confirmed invasive breast cancer who were undergoing NST were included (mean age, 54 years; range, 27-84 years). Breast MR imaging was performed before and after treatment. Presence of late enhancement was assessed. Apparent diffusion coefficients (ADCs) were obtained by using two different methods. ADC ratio (mean posttreatment ADC/mean pretreatment ADC) was calculated. pCR was defined as absence of any residual invasive cancer or DCIS. Multivariate regression analysis and receiver operating characteristic analysis were performed. Results According to their immunohistochemical (IHC) profile, tumors were classified as human epidermal growth factor receptor 2 (HER2) positive (n = 51), estrogen receptor (ER) positive/HER2 negative (n = 40), and triple negative (n = 20). pCR was achieved in 19% (21 of 111) of cases; 86% of them were triple-negative or HER2-positive subtypes. Absence of late enhancement at posttreatment MR imaging was significantly associated with pCR (area under the curve [AUC], 0.85). Mean ADC ratio significantly increased when pCR was achieved (P < .001). A κ value of 0.479 was found for late enhancement (P < .001), and the intraclass correlation coefficient for ADCs was 0.788 (P < .001). Good correlation of ADCs obtained with the single-value method and those obtained with the mean-value methods was observed. The model combining the IHC subtype, ADC ratio, and late enhancement had the highest association with pathologic response, achieving an AUC of 0.92 (95% confidence interval: 0.86, 0.97). Conclusion Triple-negative or HER2-positive tumors showing absence of late enhancement and high ADC ratio after NST are associated with pCR.©RSNA, 2016 Online supplemental material is available for this article.
authors.affiliation: From the Departments of Radiology (G.S., X.B., M.V.), Pathology (P.L.F.), Radiation Oncology (B.F.), and Gynecology and Obstetrics (X.C.), Hospital Clínic de Barcelona and University of Barcelona Medical School, Villarroel 170, 08036 Barcelona, Spain; and Institut d'Investigacions August Pi i Sunyer, Barcelona, Spain (P.L.F.).
authors.forename: Gorane
authors.initials: G
authors.lastname: Santamaría
authors.affiliation: From the Departments of Radiology (G.S., X.B., M.V.), Pathology (P.L.F.), Radiation Oncology (B.F.), and Gynecology and Obstetrics (X.C.), Hospital Clínic de Barcelona and University of Barcelona Medical School, Villarroel 170, 08036 Barcelona, Spain; and Institut d'Investigacions August Pi i Sunyer, Barcelona, Spain (P.L.F.).
authors.forename: Xavier
authors.initials: X
authors.lastname: Bargalló
authors.affiliation: From the Departments of Radiology (G.S., X.B., M.V.), Pathology (P.L.F.), Radiation Oncology (B.F.), and Gynecology and Obstetrics (X.C.), Hospital Clínic de Barcelona and University of Barcelona Medical School, Villarroel 170, 08036 Barcelona, Spain; and Institut d'Investigacions August Pi i Sunyer, Barcelona, Spain (P.L.F.).
authors.forename: Pedro Luis
authors.initials: PL
authors.lastname: Fernández
authors.affiliation: From the Departments of Radiology (G.S., X.B., M.V.), Pathology (P.L.F.), Radiation Oncology (B.F.), and Gynecology and Obstetrics (X.C.), Hospital Clínic de Barcelona and University of Barcelona Medical School, Villarroel 170, 08036 Barcelona, Spain; and Institut d'Investigacions August Pi i Sunyer, Barcelona, Spain (P.L.F.).
authors.forename: Blanca
authors.initials: B
authors.lastname: Farrús
authors.affiliation: From the Departments of Radiology (G.S., X.B., M.V.), Pathology (P.L.F.), Radiation Oncology (B.F.), and Gynecology and Obstetrics (X.C.), Hospital Clínic de Barcelona and University of Barcelona Medical School, Villarroel 170, 08036 Barcelona, Spain; and Institut d'Investigacions August Pi i Sunyer, Barcelona, Spain (P.L.F.).
authors.forename: Xavier
authors.initials: X
authors.lastname: Caparrós
authors.affiliation: From the Departments of Radiology (G.S., X.B., M.V.), Pathology (P.L.F.), Radiation Oncology (B.F.), and Gynecology and Obstetrics (X.C.), Hospital Clínic de Barcelona and University of Barcelona Medical School, Villarroel 170, 08036 Barcelona, Spain; and Institut d'Investigacions August Pi i Sunyer, Barcelona, Spain (P.L.F.).
authors.forename: Martin
authors.initials: M
authors.lastname: Velasco
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000145:classification / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D003287:Contrast Media; D038524:Diffusion Magnetic Resonance Imaging; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D003287:Contrast Media